Hengrui Medicine: Subsidiary HRS-5765 Tablets Approved for Clinical Trials

Hengrui Medicine announced that its subsidiary, Chengdu Shengdi Medicine Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for HRS-5765 tablets. The application indication is for the treatment of heart failure. HRS-5765 tablets is a category 1 new drug independently developed by the company. Preclinical data shows that HRS-5765 can significantly improve heart function and disease progression. According to the inquiry, there are currently no similar drugs approved for marketing domestically and internationally. As of now, the total research and development investment for the HRS-5765 tablet project is approximately 13.8 million RMB.